Presence of maternal anti-HBs antibodies does not influence hepatitis B vaccine response in Brazilian neonates

AUTOR(ES)

Junqueira, Ana Luiza N, Tavares, Viviane R, Martins, Regina MB, Frauzino, Kamilla V, Costa e Silva, Agabo M da, Rodrigues, Izolina MX, Minamisava, Ruth, Teles, Sheila A

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

2011-02

RESUMO

Recently, it was suggested that maternal hepatitis B surface antigen antibodies (anti-HBs) acquired transplacentally could play a negative role in newborn infants' immune response to the hepatitis B vaccine. We compared the hepatitis B virus (HBV) vaccine response in infants born to mothers previously vaccinated against HBV (n = 91) to infants born to mothers who were not previously vaccinated (n = 221). All newborn infants received three intramuscular doses (10 μg) of HBV vaccine (Butang®) at 0,1 and six months. The first dose was administered at the maternity hospital within 12 h of birth. The geometric mean titres of anti-HBs were not different among newborn infants born to mothers who were anti-HBs-negative (492.7 mIU/mL) and anti-HBs-positive (578.7 mIU/mL) (p = 0.38). Eight infants did not respond to the HBV vaccine. Of them, six were born to anti-HBs-negative mothers and two were born to mothers with anti-HBs titres less than 50 mlU/mL. Despite the mother's anti-HBs-positive status, our data show a good immunogenicity of the Brazilian HBV recombinant vaccine in neonates.

Documentos Relacionados

• Vacinação contra hepatite B e Anti-HBS entre trabalhadores da saúde
• Anti-HBs Cellular Immune Response in Kidney Recipients before and 4 Months after Transplantation
• Mutations in the S gene and in the overlapping reverse transcriptase region in chronic hepatitis B Chinese patients with coexistence of HBsAg and anti-HBs
• Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load
• Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.